Ankylosing spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

By

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

By

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

By

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

By

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

By

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

By

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

By

Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

By

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

By

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

By

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

By

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

By

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

By

Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

By

Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

By

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

Etanercept for Spondyloarthritis: Impact on Disease Progression

By

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

By

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Online Consultation System Benefits Rheumatic Disease Management

Online Consultation System Benefits Rheumatic Disease Management

The SSDM series of applications is cost-effective for patients of rheumatologists.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

By

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

By

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

By

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

FDA Approval of Biosimilar Cyltezo for Multiple Indications

FDA Approval of Biosimilar Cyltezo for Multiple Indications

By

Cyltezo subcutaneous injection has been approved by the FDA.

BMI and Treatment Response to TNF Inhibitors in Ankylosing Spondylitis

BMI and Treatment Response to TNF Inhibitors in Ankylosing Spondylitis

By

In patients with AS, those with a BMI in the overweight or obese range had a lower likelihood of clinical improvement with tumor necrosis factor inhibitor therapy.

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

By

A study analyzes whether underlying sacroiliac erosions may be present in patients with nonradiographic axial spondylarthritis who have normal radiographs.

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

By

Serum leptin and high molecular weight adiponectin have an inverse relationship with radiographic spinal progression in patients with ankylosing spondylitis.

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

By

Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.

Anti-TNF-α Rx Improves Sleep in Ankylosing Spondylitis

Anti-TNF-α Rx Improves Sleep in Ankylosing Spondylitis

Patients saw a reduction in PSQI scores, but no change in polysomnography parameters.

Abnormal Chest Radiograph in Uveitis Often Sarcoidosis

Abnormal Chest Radiograph in Uveitis Often Sarcoidosis

Patients with panuveitis more often had biopsy-confirmed sarcoidosis than those with other anatomical locations of uveitis (20% vs 4%).

Systemic Therapy Associated With Improved Visual Acuity in Uveitis

Systemic Therapy Associated With Improved Visual Acuity in Uveitis

At seven-year follow-up, visual acuity was better with systemic therapy than with intravitreous fluocinolone acetonide implants.

MTX + Adalimumab Effective in JIA-Associated Uveitis

MTX + Adalimumab Effective in JIA-Associated Uveitis

In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.

Sign Up for Free e-newsletters